Prolonged improvement after rituximab: Two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis

Journal of Clinical Neuromuscular Disease

Volumn 12, Issue 2, 2010, Pages 85-87

  Burusnukul, Prinyarat ^a   Brennan, Thomas D ^a   Cupler, Edward J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Musclespecific tyrosine kinase; Myasthenia gravis; Refractory; Rituximab; Seronegative

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN; MUSCLE SPECIFIC PROTEIN TYROSINE KINASE; PREDNISONE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DIPLOPIA; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; FATIGUE; FEMALE; HUMAN; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PTOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; DRUG RESISTANCE; FEMALE; HUMANS; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RECOVERY OF FUNCTION; TIME; TREATMENT OUTCOME;

EID: 78651479146     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e3181fcc109     Document Type: Article

References (10)

1. Vincent A, Sanders DB, Drachman DB, et al. Multicenter study of clinical, geographical and ethnic features of MuSK-antibody-associated myasthenia gravis. Ann Neurol. 2004;56(Suppl 8): S63.
2. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol. 2007;254:968-969.
3. Evoli A, Tonali P, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304-2311.
4. Pasnoor M, Wolfe G, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience. Muscle Nerve. 2010;41:370-374.
5. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol. 2004;4:398-402.
6. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports project. Blood. 2009;113:4834-4840.
7. Jaretzki A, Barohn, R, Ernstoff, R, et al. Myasthenia gravis. Recommendations for clinical research standards. Neurology. 2000;55:16-23.
8. Takagi K, Yoshida A, Iwasaki H, et al. Anti CD 20 antibody (rituxuimab) therapy in a myasthenia gravis patient with follicular lymphoma. Ann Hematol. 2005;84:548-550.
9. Zebardast N, Patwa H, Novella S, et al. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve online. 2010;41:375-378.
10. Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006;33:575-580.